IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 311 filers reported holding IONIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.49 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $40,771,927 | +26.6% | 898,852 | +14.5% | 0.05% | +32.4% |
Q2 2023 | $32,217,084 | +10.3% | 785,208 | -3.9% | 0.04% | +5.7% |
Q1 2023 | $29,210,588 | -0.8% | 817,308 | +4.9% | 0.04% | -2.8% |
Q4 2022 | $29,441,526 | -17.3% | 779,495 | -3.1% | 0.04% | -20.0% |
Q3 2022 | $35,605,000 | +19.7% | 804,083 | +0.1% | 0.04% | +32.4% |
Q2 2022 | $29,752,000 | -2.1% | 803,664 | -2.0% | 0.03% | +21.4% |
Q1 2022 | $30,379,000 | +34.3% | 820,164 | +10.4% | 0.03% | +47.4% |
Q4 2021 | $22,614,000 | +59.8% | 743,164 | +76.1% | 0.02% | +26.7% |
Q3 2021 | $14,153,000 | -9.7% | 421,964 | +0.0% | 0.02% | -6.2% |
Q2 2021 | $15,668,000 | -17.9% | 421,864 | -0.6% | 0.02% | -23.8% |
Q1 2021 | $19,089,000 | -12.4% | 424,579 | +10.2% | 0.02% | -19.2% |
Q4 2020 | $21,787,000 | +64.2% | 385,344 | +37.8% | 0.03% | +44.4% |
Q3 2020 | $13,269,000 | +8.7% | 279,647 | +35.1% | 0.02% | +5.9% |
Q2 2020 | $12,207,000 | +169.6% | 207,042 | +116.2% | 0.02% | +112.5% |
Q1 2020 | $4,528,000 | +78.9% | 95,765 | +128.5% | 0.01% | +100.0% |
Q4 2019 | $2,531,000 | -10.3% | 41,903 | -11.0% | 0.00% | 0.0% |
Q3 2019 | $2,822,000 | -9.8% | 47,103 | -3.3% | 0.00% | -20.0% |
Q2 2019 | $3,130,000 | -46.0% | 48,703 | -31.8% | 0.01% | -44.4% |
Q1 2019 | $5,796,000 | +398.8% | 71,403 | +232.1% | 0.01% | +350.0% |
Q4 2018 | $1,162,000 | +14.9% | 21,503 | +9.7% | 0.00% | +100.0% |
Q3 2018 | $1,011,000 | +12.3% | 19,603 | -9.3% | 0.00% | 0.0% |
Q2 2018 | $900,000 | -7.6% | 21,603 | -2.3% | 0.00% | 0.0% |
Q1 2018 | $974,000 | -19.6% | 22,103 | -8.3% | 0.00% | -50.0% |
Q4 2017 | $1,212,000 | +34.2% | 24,103 | +35.4% | 0.00% | +100.0% |
Q3 2017 | $903,000 | -5.5% | 17,803 | -5.3% | 0.00% | -50.0% |
Q2 2017 | $956,000 | -25.9% | 18,800 | -41.4% | 0.00% | 0.0% |
Q1 2017 | $1,290,000 | -19.7% | 32,100 | -4.5% | 0.00% | -33.3% |
Q4 2016 | $1,607,000 | +352.7% | 33,600 | +246.4% | 0.00% | +200.0% |
Q3 2016 | $355,000 | -24.3% | 9,700 | -51.8% | 0.00% | 0.0% |
Q2 2016 | $469,000 | -37.4% | 20,120 | +8.8% | 0.00% | 0.0% |
Q1 2016 | $749,000 | -34.6% | 18,500 | 0.0% | 0.00% | -50.0% |
Q4 2015 | $1,146,000 | – | 18,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |